Autolus Announces Proposed Public Offering in the United States
February 08, 2021 16:19 ET
|
Autolus Therapeutics plc
LONDON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 4
February 04, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics provides business outlook for 2021 & 2022
January 06, 2021 04:07 ET
|
Autolus Therapeutics plc
• Company prioritizes AUTO1, a potentially transformational treatment for Adult Acute Lymphoblastic Leukemia (ALL), with full data from the AUTO1-AL1 study expected in 2022• Company intends to partner...
Autolus Therapeutics to participate in Investor Conferences through January
January 04, 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the 62nd ASH Annual Meeting
December 07, 2020 12:01 ET
|
Autolus Therapeutics plc
AUTO3 continues to show a differentiated product profile supporting outpatient administration Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec....
Autolus Therapeutics presents compelling AUTO1 data from ALLCAR Phase 1 study in Adult Acute Lymphoblastic Leukemia (ALL) during the 62nd ASH Annual Meeting
December 05, 2020 15:01 ET
|
Autolus Therapeutics plc
Updated data from the ALLCAR study suggests AUTO1’s potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm...
Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine
November 30, 2020 07:00 ET
|
Autolus Therapeutics plc
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach...
Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference
November 17, 2020 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Reports Third Quarter 2020 Financial Results and Operational Progress
November 05, 2020 07:00 ET
|
Autolus Therapeutics plc
LONDON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Report Third Quarter 2020 Financial Results and Host Conference Call on November 5
October 30, 2020 07:00 ET
|
Autolus Therapeutics plc
LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...